secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001725160-24-000157
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis Q2 cash $426.4M; FDA partial hold on azenosertib; CMO resigns
----------------------------------------------------------------------

- Cash, equivalents and marketable securities $426.4M as of June 30; R&D expense $48.4M (Q2 2024); cash runway into mid-2026.
- FDA placed partial clinical hold on azenosertib June 18 after two deaths in DENALI study; resolution timelines uncertain.
- Discontinued development of BCL-2 inhibitor ZN-d5; combination with azenosertib in AML phase 1 stopped.
- CMO Diana Hausman stepped down effective Aug 8; CEO Kimberly Blackwell appointed Interim CMO; replacement search ongoing.
- Expected 2H milestones: DENALI Cohort 1b topline, azenosertib Phase 1b final results, MAMMOTH data with GSK, others.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000157/0001725160-24-000157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000157/zntl-20240809.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer